Customization: | Available |
---|---|
Powder: | Yes |
Customized: | Customized |
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited by an independent third-party inspection agency
Product Name | Pazopanib |
Latin Name | Pazopanib for research;5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide;Pazopanib |
CAS NO | 444731-52-6 |
MF | C21H23N7O2S |
MW | 437.52 |
Assay | 99% |
Melting point | 285-289°C (dec.) |
Boiling point | 728.8±70.0 °C(Predicted) |
Density | 1.40 |
Storage conditions | Refrigerator |
Pazopanib is an oral multi-targeted tyrosine kinase inhibitor that blocks multiple receptors including VEGFR1-3, PDGFR-α, PDGFR-β and c-KIT. Sorafenib and sunitinib are very similar.
Pazopanib Indications:
1. FDA-approved for patients with advanced kidney bad cells.
2. FDA-approved for patients with advanced soft tissue sarcoma (STS) who have previously received chemotherapy.
Capecitabine | Everolimus | Afatinib | Vandetanib | Gefitinib |
Temozolomid | Rapamycin | Axitinib | Sorafenib tosylate | Cediranib |
Cabozantinib | Selumetinib | Crizotinib | Sunitinib malate | Erlotinib |
Crizotinib | Lapatinib | Debrafenib | Cabazitaxel | Ponatinib |
1. Customs clearance